Recent trends in the number of patients with pathology samples indicating cancer in Northern Ireland (excludes samples from Altnagelvin Laboratory)

October 2021 Update

Acknowledgements: The Northern Ireland Cancer Registry (NICR) is funded by the Public Health Agency. NICR uses data provided by patients and collected by the health service as part of their care and support.







Contents

	<u>Page</u>
Summary	3
Patients with pathology samples indicating cancer - All persons	6
Patients with pathology samples indicating cancer - Males	7
Patients with pathology samples indicating cancer - Females	8
Patients with pathology samples indicating cancer - Ages 0-69	9
Patients with pathology samples indicating cancer - Ages 70 and over	10
Patients with pathology samples indicating bowel cancer - All persons	11
Patients with pathology samples indicating bowel cancer - All persons, screening age	12
Patients with pathology samples indicating lung cancer - All persons	13
Patients with pathology samples indicating breast cancer - Females	14
Patients with pathology samples indicating breast cancer - Females, screening age	15
Patients with pathology samples indicating prostate cancer - Males	16
Patients with pathology samples indicating gynaecological cancer - Females	17
Patients with pathology samples indicating upper gastrointestinal cancer - All persons	18
Patients with pathology samples indicating head & neck cancer - All persons	19
Patients with pathology samples indicating urinary cancer - All persons	20
Patients with pathology samples indicating haematological cancer - All persons	21
Patients with pathology samples indicating malignant melanoma - All persons	22
Patients with pathology samples indicating non-melanoma skin cancer - All persons	23
Patients with pathology samples indicating other cancer - All persons	24
Notes	25


SUMMARY

Recent trends in the number of patients with pathology samples indicating cancer: Oct-21

- 1) This summary provides an overview of recent trends in the number of patients with pathology samples indicating cancer (excluding non-melanoma skin cancer, NMSC) whose first sample was taken from Jan-20 to Oct-21 in Northern Ireland.
- 2) These trends are contrasted with the annual average number of patients with pathology samples indicating cancer (ex NMSC) during 2017-2019 in order to provide an indication of the potential impact of the Covid-19 restrictions on diagnostic cancer services.
- 3) Data are sourced from three of the four NHS pathology laboratories in NI (Belfast, Antrim, Craigavon), which are usually provided to NICR on a monthly basis. **Altnagelvin laboratory is excluded as a change in recording systems led to an undercount in the number of reported samples in Jan-Apr 2021.**


Trends in patients with pathology samples indicating cancer by month and year first sample taken

4) From Mar-20 to Oct-21 the number of patients with a pathological sample indicating cancer was 5.8% lower than the average number for the same time period in 2017-2019.




Year sample					Mo	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	658	553	609	579	688	604	598	607	613	680	635	544
2020	660	588	557	336	456	573	540	527	608	569	664	598
2021	519	537	701	623	645	693	576	580	620	600		
*Annual average												

- 5) From Mar-20 to Oct-21 there was a 5.2% decrease among males and a 6.3% decrease among females compared to 2017-2019. A decrease of 6.8% occurred in the number of patients aged 0-69 years, while there was a decrease of 4.5% among those aged 70 and older.
- 6) Compared to the annual average in 2017-2019, from Mar-20 to Oct-21 the number of patients with a pathology sample indicating lung cancer decreased by 19.0%, while those indicating prostate cancer decreased by 5.9%. Increases were recorded for bowel cancer and haematological cancer, while decreases of more than 10% occurred for gynaecological cancer, head and neck cancer, urinary cancer and non-melanoma skin cancer.



Trends in patients with pathology samples indicating cancer by week and year first sample taken

7) There was an 3.6% decrease in the number of patients with a pathology sample indicating cancer in the twelve weeks up to 30-Oct-21 compared to the average value in the equivalent weeks in 2017-2019.




Year sample taken					We	ek sam	ple take	n**				
	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21
2017-2019*	140	133	112	157	138	147	154	158	161	144	150	119
2020	125	152	142	105	146	122	141	142	142	122	146	114
2021	149	128	123	114	137	145	135	150	148	156	155	111

^{*}Annual average


^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.

- 8) In the twelve weeks up to 30-Oct-21 there was a 3.7% decrease in male patients and a 3.4% decrease in female patients compared to the same time period in 2017-2019. A decrease of 2.2% occurred in the number of patients aged 0-69 years, while there was a decrease of 5.4% among those aged 70 and older.
- 9) Compared to the annual average in 2017-2019, in the twelve weeks up to 30-Oct-21 the number of patients with a pathology sample indicating lung cancer decreased by 18.6%, while those indicating female breast cancer decreased by 5.6%. Increases were recorded for bowel cancer and upper GI cancer, while decreases of more than 10% occurred for head and neck cancer and non-melanoma skin cancer.




Patients with pathology samples indicating cancer (ex NMSC): All persons

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					Mo	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	658	553	609	579	688	604	598	607	613	680	635	544
2020	660	588	557	336	456	573	540	527	608	569	664	598
2021	519	537	701	623	645	693	576	580	620	600		
*Annual average	•											




Year sample					We	eek sam	ple take	n**				
taken	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21
2017-2019*	140	133	112	157	138	147	154	158	161	144	150	119
2020	125	152	142	105	146	122	141	142	142	122	146	114
2021	149	128	123	114	137	145	135	150	148	156	155	111

^{*}Annual average


^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.

Patients with pathology samples indicating cancer (ex NMSC): Males

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					Mo	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	320	257	297	280	328	291	280	281	291	320	301	249
2020	308	284	262	158	244	282	248	230	275	245	357	297
2021	232	257	360	282	322	332	277	275	300	277		
*Annual average	•											




Year sample					We	eek sam	ple take	n**				
taken	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21
2017-2019*	65	65	53	73	66	70	73	74	77	69	71	57
2020	52	63	62	51	62	54	72	61	59	50	65	49
2021	61	67	60	50	72	70	72	64	80	72	64	51

^{*}Annual average

^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.


Patients with pathology samples indicating cancer (ex NMSC): Females

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					Mo	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	338	295	312	299	360	313	317	326	322	360	333	295
2020	352	304	295	178	212	291	292	297	333	324	307	301
2021	287	280	341	341	323	361	299	305	320	323		

Trends in patients with pathology samples indicating cancer by week and year first sample taken




Year sample					We	eek sam	ple take	n**				
taken	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21
2017-2019*	75	68	59	84	72	76	80	84	84	76	79	62
2020	73	89	80	54	84	68	69	81	83	72	81	65
2021	88	61	63	64	65	75	63	86	68	84	91	60

^{*}Annual average

^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.


Patients with pathology samples indicating cancer (ex NMSC): Ages 0 to 69

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					Mo	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	387	327	354	332	384	333	338	341	351	383	349	309
2020	357	332	325	202	265	311	282	292	325	326	378	339
2021	301	311	400	376	354	371	318	323	353	352		

Trends in patients with pathology samples indicating cancer by week and year first sample taken




Year sample					We	eek sam	ple take	n**				
taken	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21
2017-2019*	82	72	61	87	84	80	90	87	90	78	94	63
2020	72	84	73	57	80	67	72	76	84	66	80	70
2021	83	68	77	59	80	77	73	96	89	86	94	65

^{*}Annual average

^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.


Patients with pathology samples indicating cancer (ex NMSC): Ages 70 and over

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					Me	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	271	226	255	247	305	271	259	266	262	297	285	234
2020	303	256	232	134	191	262	258	235	283	243	286	259
2021	218	226	301	247	291	322	258	257	267	248		

Trends in patients with pathology samples indicating cancer by week and year first sample taken




V					We	eek sam	ple take	n**				
Year sample taken	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21
2017-2019*	58	61	51	70	54	66	64	71	72	66	56	55
2020	53	68	69	48	66	55	69	66	58	56	66	44
2021	66	60	46	55	57	68	62	54	59	70	61	46

^{*}Annual average


^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.

Patients with pathology samples indicating bowel cancer: All persons

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					M	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	73	65	74	74	81	70	67	74	70	75	84	67
2020	84	76	70	35	45	70	71	73	82	61	58	71
2021	66	80	84	97	86	73	74	87	80	79		
*Annual average	•											




V					We	eek sam	ple take	n**				
Year sample taken	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21
2017-2019*	20	17	16	18	15	18	18	17	16	17	16	14
2020	15	26	17	16	18	20	14	22	17	15	11	12
2021	24	13	16	20	18	17	17	21	13	17	17	26

^{*}Annual average


^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.

Patients with pathology samples indicating bowel cancer: All persons, screening age (60-74)

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					M	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	34	28	33	30	34	27	28	32	31	33	40	27
2020	41	31	42	14	17	37	33	18	30	23	28	29
2021	27	42	42	45	35	34	34	33	29	34		
*Annual average												




V					We	eek sam	ple take	n**				
Year sample taken	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21
2017-2019*	10	6	6	9	6	8	7	7	8	6	8	6
2020	7	2	4	3	9	8	4	11	4	8	5	2
2021	6	8	7	6	7	5	10	6	7	6	8	11

^{*}Annual average

^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.


Patients with pathology samples indicating lung cancer: All persons

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					Mo	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	51	43	43	44	53	47	51	49	52	52	50	35
2020	56	52	37	22	36	43	39	39	38	34	38	40
2021	26	35	33	42	43	39	41	36	46	40		

Trends in patients with pathology samples indicating cancer by week and year first sample taken




V					We	eek sam	ple take	n**				
Year sample taken	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21
2017-2019*	11	11	9	13	13	14	12	14	14	11	9	9
2020	13	7	10	6	10	5	12	6	8	6	9	10
2021	9	9	9	4	8	11	14	10	18	8	9	5

^{*}Annual average

^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.


Patients with pathology samples indicating breast cancer: Females

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					Mo	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	116	94	108	93	120	93	101	103	106	116	101	97
2020	93	102	92	62	58	89	93	104	118	123	107	103
2021	121	97	125	116	122	130	101	89	101	106		

Trends in patients with pathology samples indicating cancer by week and year first sample taken




V					We	eek sam	ple take	n**				
Year sample taken	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21
2017-2019*	23	22	16	30	24	23	27	27	25	24	28	19
2020	25	25	32	17	28	24	29	28	27	29	32	27
2021	25	15	18	23	16	20	26	27	30	23	38	11

^{*}Annual average


^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.

Patients with pathology samples indicating breast cancer: Females, screening age (50-70)

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					M	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	61	50	51	41	57	44	52	54	53	62	48	51
2020	44	44	50	32	22	35	40	58	65	68	65	55
2021	67	61	84	68	66	70	47	45	53	62		
*Annual average	1											




V					We	eek sam	ple take	n**				
Year sample taken	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-Oct- 21
2017-2019*	11	13	8	16	13	10	14	15	12	15	14	11
2020	14	15	15	10	14	13	17	13	17	18	19	12
2021	14	7	5	14	12	7	7	22	18	10	25	7

^{*}Annual average


^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.

Patients with pathology samples indicating prostate cancer: Males

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					Mo	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	79	59	75	61	89	69	69	60	58	88	75	53
2020	75	62	67	40	78	67	37	39	46	53	137	79
2021	42	51	118	63	70	88	39	57	86	57		
*Annual average												




V					We	eek sam	ple take	n**				
Year sample taken	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21
2017-2019*	13	12	17	14	15	12	16	21	23	19	17	14
2020	10	14	9	4	11	10	11	13	11	8	17	14
2021	16	11	17	15	21	23	21	11	23	15	12	7

^{*}Annual average


^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.

Patients with pathology samples indicating gynaecological cancer: Females

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					Mo	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	58	49	58	48	60	60	55	56	56	58	50	49
2020	60	43	42	32	38	41	42	38	54	59	53	48
2021	31	42	51	40	38	54	50	64	52	46		
*Annual average	•											




V					We	eek sam	ple take	n**				
Year sample taken	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21
2017-2019*	11	11	11	14	14	14	12	13	14	11	13	13
2020	14	8	6	11	14	12	9	14	14	16	12	11
2021	19	12	14	7	13	14	11	10	11	11	12	11

^{*}Annual average


^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.

Patients with pathology samples indicating upper gastrointestinal cancer: All persons

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					Mo	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	31	24	29	28	26	28	30	29	32	27	28	23
2020	42	28	22	14	17	27	22	19	30	31	28	29
2021	18	24	35	28	23	36	37	20	34	35		
*Annual average												




^{*}Annual average


^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.

Patients with pathology samples indicating head & neck cancer: All persons

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					M	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	31	22	23	27	30	30	25	32	30	34	32	28
2020	31	20	20	12	15	21	31	26	23	26	30	30
2021	22	41	30	26	23	22	23	23	25	27		
*Annual average	•											




V					We	eek sam	ple take	n**				
Year sample taken	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21
2017-2019*	8	4	6	8	8	6	7	7	7	9	8	6
2020	6	7	5	5	4	3	6	7	7	3	7	7
2021	8	2	5	3	6	7	7	4	4	7	6	9

^{*}Annual average


^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.

Patients with pathology samples indicating urinary cancer: All persons

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					Mo	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	57	58	53	55	52	52	46	56	48	44	49	46
2020	52	41	47	27	39	54	56	45	44	36	48	38
2021	45	34	53	43	60	59	52	46	39	49		
*Annual average												




V 1.					We	eek sam	ple take	n**				
Year sample taken	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21
2017-2019*	13	12	8	13	7	11	14	11	11	9	11	6
2020	9	14	13	6	13	6	14	9	10	7	10	5
2021	9	15	11	10	8	8	9	10	10	18	12	6

^{*}Annual average


^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.

Patients with pathology samples indicating haematological cancer: All persons

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					Mo	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	53	38	48	49	64	52	46	50	51	62	56	53
2020	61	53	55	32	47	59	47	50	64	48	58	55
2021	47	57	62	65	59	79	63	53	58	42		
*Annual average	•											




Year sample					We	eek sam	ple take	n**				
taken	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21
2017-2019*	8	13	9	12	10	13	13	14	15	12	15	12
2020	11	19	13	12	14	9	20	16	12	6	15	8
2021	12	14	10	13	12	13	8	16	11	13	9	7

^{*}Annual average


^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.

Patients with pathology samples indicating malignant melanoma: All persons

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample					M	onth san	nple tak	en				
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	24	28	27	28	32	27	32	25	32	38	37	26
2020	40	30	37	17	14	19	19	27	24	15	34	22
2021	24	18	29	32	31	34	27	30	34	40		
*Annual average												




Year sample					We	eek sam	ple take	n**				
taken	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21
2017-2019*	9	7	3	7	6	9	8	9	11	10	7	6
2020	7	8	10	4	7	4	6	4	4	3	4	3
2021	4	6	8	8	7	7	4	10	5	12	10	11

^{*}Annual average


^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.

Patients with pathology samples indicating non-melanoma skin cancer: All persons

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample	Month sample taken											
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	0ct	Nov	Dec
2017-2019*	393	344	325	310	366	367	318	344	378	401	424	304
2020	435	358	295	61	140	244	232	238	311	305	384	268
2021	231	286	288	333	271	339	242	249	317	294		
*Annual average	•											




Year sample taken		Week sample taken**											
	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21	
2017-2019*	76	77	74	89	93	98	86	85	91	92	90	75	
2020	68	71	50	45	70	79	81	53	75	83	81	49	
2021	59	55	60	50	72	77	76	63	80	76	69	56	

^{*}Annual average


^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.

Patients with pathology samples indicating other cancer: All persons

Trends in patients with pathology samples indicating cancer by month and year first sample taken



Year sample	Month sample taken											
taken	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2017-2019*	78	61	64	63	66	64	69	65	68	82	72	60
2020	66	65	70	39	55	69	80	55	97	73	66	64
2021	74	60	83	66	85	75	73	55	67	69		
*Annual average	•											



Year sample taken		week sample taken**											
	14-Aug- 21	21-Aug- 21	28-Aug- 21	04-Sep- 21	11-Sep- 21	18-Sep- 21	25-Sep- 21	02-0ct- 21	09-0ct- 21	16-0ct- 21	23-0ct- 21	30-0ct- 21	
2017-2019*	16	15	11	16	19	16	16	19	18	13	22	12	
2020	8	12	19	18	22	23	20	20	20	14	17	16	
2021	11	14	10	12	14	17	13	21	12	18	16	18	

^{*}Annual average

^{**} The date of the end of the week in which the sample was taken in 2021. Data for previous years refers to the equivalent Sun-Sat week in those years.

Notes:

- 1. NMSC: Non-melanoma skin cancer
- 2. Data is sourced from three of the four NHS pathology laboratories in Northern Ireland (Antrim, Belfast, Craigavon), which is provided to the NI Cancer Registry on a monthly basis. It does not include information on pathology samples processed by private laboratories.
- 3. Figures represent the number of patients with pathology samples that indicated a malignant tumour and had this result coded and recorded by the end of Oct-21. Due to potential reporting delays, pathology data from the month following Oct-21 are used in compiling the presented results.
- 4. Assignment of week number is based upon a Sunday to Saturday week. The week ending label used in graphs and tables is based upon the date of the end of the week (a Saturday) in 2020/2021. This is compared with the equivalent Sunday-Saturday week in 2017-2019, although the actual date ending this week in 2017-2019 will differ.
- 5. Individual patients with cancer may have more than one pathology sample. A diagnosis of cancer may be a result of more than one procedure indicating cancer, for example a breast cancer diagnosis may be based upon a positive biopsy of the breast and then a separate positive dissection of a lymph node. Patients are thus only included once per cancer type unless they have had pathology samples separated by more than two years, thus a patient with samples in March and April of 2019 will be counted once (in the March 2019 count), while a patient with samples in April 2017 and May 2020 will be counted in both the April 2017 and May 2020 counts.
- 6. Cancer types are defined as follows:

Bowel cancer: Includes colon, rectum and rectosigmoid junction (ICD10 codes: C18-C20)

Lung cancer: Includes lung and trachea (ICD10 codes: C33-C34) **Breast cancer:** Includes female breast only (ICD10 codes: C50)

Prostate cancer: (ICD10 codes: C61)

Gynaecological cancer: Includes uterus, ovary, cervix, vulva, vagina, placenta and other female genital (ICD10

codes: C51-C58)

Upper GI cancer: Includes oesophagus and stomach (ICD10 codes: C15, C16).

Head and neck cancer: Includes lip, tongue, mouth, parotid & salivary glands, tonsil, oropharynx, nasopharynx, pyriform sinus, hypopharynx, nasal cavity, middle ear, sinuses and larynx (ICD10 codes: C00-C14, C30-C32)

Urinary cancer: Includes kidney, renal pelvis, ureter, bladder and other urinary (ICD10 codes: C64-C68). **Haematological cancer:** Includes lymphoma (all types), leukaemia (all types), myeloma, malignant

immunoproliferative disease and other lymphoid and haematopoietic (ICD10 codes: C81-C96)

Melanoma: (ICD10 code: C43)

Non-melanoma skin cancer (NMSC): (ICD10 code: C44)

C60, C62, C63, C69-C75). Excludes cancer of unknown primary."

Acknowledgements

The Northern Ireland Cancer Registry (NICR) is funded by the Public Health Agency. NICR uses data provided by patients and collected by the health service as part of their care and support.

Further Information

Further data is available at: www.qub.ac.uk/nicr

Phone: +44 (0)28 9097 6028 e-mail: nicr@gub.ac.uk





